Literature DB >> 16684511

Increased isoform-specific membrane translocation of conventional and novel protein kinase C in human neuroblastoma SH-SY5Y cells following prolonged hypoxia.

Junfa Li1, Yanming Qu, Pengyu Zu, Song Han, Ge Gao, Qunyuan Xu, Li Fang.   

Abstract

Several studies have suggested that protein kinase C (PKC) plays a key role in the mechanism of cerebral ischemic/hypoxic preconditioning (I/HPC). However, detailed information regarding PKC isoforms in response to brain ischemia/hypoxia and their potential role in neuroprotection is unclear. Previous studies in our laboratory have demonstrated that the levels in membrane translocation of conventional PKC (cPKC) betaII, gamma, and novel PKCepsilon (nPKC), but not cPKCalpha, betaI, nPKCdelta, eta, mu, theta, and atypical PKC (aPKC) zeta and iota/lambda, were increased significantly in the hippocampus and cortex of intact mice with hypoxic preconditioning. To further detect cPKC and nPKC isoforms activation following prolonged hypoxia in vitro, we tested the membrane translocation (an indicator of PKC activation) of cPKCalpha, betaI, betaII, and gamma, and nPKCdelta, epsilon, eta, mu, and theta in a human neuroblastoma SH-SY5Y cell line following sustained hypoxic exposure (1% O(2)/5% CO(2)/94% N(2)). Using Western blot and immunocytochemistry methods, we found that the levels of cPKCalpha, betaI, betaII, and nPKCepsilon, but not nPKCdelta, eta, mu, and theta, membrane translocation were increased significantly (P < 0.05, n = 8) in a time-dependent manner (from 0.5 to 24 h) following sustained hypoxic exposure. Similarly, the immunostaining experiment also showed a noticeable translocation of cPKCalpha, betaI, betaII, and nPKCepsilon from the cytosol to the perinuclear or membrane-related areas after 6 h posthypoxic exposure. In addition, no cPKCgamma was detected in this cell line under either a normoxic or hypoxic condition. These results suggested that prolonged hypoxia may induce the activation of cPKCalpha, betaI, betaII, and nPKCepsilon by triggering their membrane translocation in SH-SY5Y cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684511     DOI: 10.1016/j.brainres.2006.03.110

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Nicotinamide Mononucleotide Adenylyltransferase 1 Protects Neural Cells Against Ischemic Injury in Primary Cultured Neuronal Cells and Mouse Brain with Ischemic Stroke Through AMP-Activated Protein Kinase Activation.

Authors:  Jia Liang; Peng Wang; Jia Wei; Cuifen Bao; Donghe Han
Journal:  Neurochem Res       Date:  2015-04-05       Impact factor: 3.996

2.  DOR activation inhibits anoxic/ischemic Na+ influx through Na+ channels via PKC mechanisms in the cortex.

Authors:  Dongman Chao; Xiaozhou He; Yilin Yang; Alia Bazzy-Asaad; Lawrence H Lazarus; Gianfranco Balboni; Dong H Kim; Ying Xia
Journal:  Exp Neurol       Date:  2012-05-15       Impact factor: 5.330

3.  Down-regulation of miRNA-30a alleviates cerebral ischemic injury through enhancing beclin 1-mediated autophagy.

Authors:  Peng Wang; Jia Liang; Yun Li; Jiefei Li; Xuan Yang; Xinxin Zhang; Song Han; Shujuan Li; Junfa Li
Journal:  Neurochem Res       Date:  2014-04-26       Impact factor: 3.996

4.  Protein kinase C regulates bombesin-induced rapid VEGF secretion in neuroblastoma cells.

Authors:  Cameron Schlegel; Pritha Paul; Sora Lee; Kwang Woon Kim; Nadja Colon; Jingbo Qiao; Dai H Chung
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

5.  Inhibition of CaMKIV relieves streptozotocin-induced diabetic neuropathic pain through regulation of HMGB1.

Authors:  Xin Zhao; Le Shen; Li Xu; Zhiyao Wang; Chao Ma; Yuguang Huang
Journal:  BMC Anesthesiol       Date:  2016-05-23       Impact factor: 2.217

6.  Identification of Protein Kinase C Isoforms Involved in Type 1 Diabetic Encephalopathy in Mice.

Authors:  Jiayin Zheng; Yue Wang; Song Han; Yanlin Luo; Xiuli Sun; Ning Zhu; Li Zhao; Junfa Li
Journal:  J Diabetes Res       Date:  2018-03-18       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.